Alimera reports net revenue of $2.2 million in second quarter

Alimera Sciences reported second quarter net revenue of $2.2 million, up from $2.1 million in the first quarter and $179,000 in the same quarter of 2013, the company announced in a news release.“We achieved an important milestone during the second quarter of 2014 as more commercial patients have now been injected with Iluvien than were treated in our clinical trials. Further, we experienced a 25% increase in Iluvien injections in the United Kingdom during the second quarter of 2014 compared to the prior quarter,” Dan Myers, Alimera president and CEO, (Read more...)

Full Story →